BMAL2 and neoplasm: In colorectal cancer, ARNTL2 is identified as a potential biomarker for tumor invasiveness and aggressiveness and ARNTL2 knockdown suppresses cell migration, invasion, and proliferation through inhibiting SMOC2-EMT expression and PI3K/AKT signaling pathway [32, 33].